EGFR and bone metastasis: Compared with radiotherapy for brain or bone metastasis, the combination of EGFR‐TKIs and thoracic radiotherapy not only significantly improved mOS predictability but also increased the OS period in patients (36.6 vs. 30.7 vs. 31.7 months).